Iovance's lifileucel-pembrolizumab combination shows 62.5% response rate in phase 2 melanoma trial
IOVA•Iovance Biotherapeutics presented final phase 2 results for lifileucel combined with pembrolizumab in frontline advanced melanoma, reporting a 62.5% response rate. The company said responses were durable and safety was consistent with the treatments' known profiles.
1. Phase 2 results
Iovance Biotherapeutics presented final phase 2 results for lifileucel combined with pembrolizumab in frontline advanced melanoma at ESMO on October 23, 2026. The combination had a 62.5% response rate, with durable tumor responses and safety consistent with the treatments' known profiles.
2. Phase 3 trial ongoing
The results support the ongoing TILVANCE-301 phase 3 trial, which is seeking to expand lifileucel's use into frontline advanced melanoma.
